Domov › Kronična limfocitna levkemija › Georgia
Klinične študije za Kronična limfocitna levkemija v Georgia
16 študij za Kronična limfocitna levkemija išče udeležence na lokacijah v Georgia.
Mesta v Georgia
Uradno besedilo študije (angleško)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Northeast Georgia Medical Center Braselton, Braselton
- Atlanta VA Medical Center, Decatur
- Northeast Georgia Medical Center-Gainesville, Gainesville
- in še 4
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Starost 40–75 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT05334069A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Augusta University, Augusta
- Southeastern Regional Medical Center, Newnan
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT05006716A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Emory University Winship Cancer Institute, Atlanta
- Northside Cancer Center, Atlanta
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT06846671Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Winship Cancer Institute Emory University, Atlanta
- Northside Hospital Cancer Institute, Atlanta
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 8. sep. 2026 · NCT03666000Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- City of Hope - Atlanta, Newnan
Vključevanje udeležencevFaza 1/2
Starost 12 in več · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT04588922Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
- Central Georgia Cancer Care, Macon
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 31. avg. 2026 · NCT07516093A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- Northside Hospital, Atlanta
Vključevanje udeležencevFaza 1Vabljeni zdravi prostovoljci
Starost 18–75 · Vsi spoli · Posodobljeno 28. jul. 2026 · NCT07020533Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 6. jul. 2026 · NCT03501576A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Winship Cancer Institute of Emory University, Atlanta
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 2. jul. 2026 · NCT05131022A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- City of Hope National Medical Center, Atlanta Cancer Center, Newnan
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 19. maj 2026 · NCT06588478Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
- City of Hope Atlanta Cancer Center, Newnan
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 13. mar. 2026 · NCT07218510CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- Northside Hospital, Atlanta
Vključevanje udeležencevFaza 2Vabljeni zdravi prostovoljci
Starost 18–75 · Vsi spoli · Posodobljeno 10. mar. 2026 · NCT06059391A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- The Emory Clinic, Atlanta
Vključevanje udeležencevFaza 4
Starost 18 in več · Vsi spoli · Posodobljeno 2. mar. 2026 · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- The Emory Clinic, Atlanta
Vključevanje udeležencevFaza 4
Starost 18 in več · Vsi spoli · Posodobljeno 2. mar. 2026 · NCT06876649Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
- Winship Cancer Institute of Emory University /ID# 230643, Atlanta
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 9. feb. 2026 · NCT04895436Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
- Winship Cancer Institute at Emory University, Atlanta
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 7. jan. 2026 · NCT06043674Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.